Abstract:To retrospectively analyze the effect of postoperative intensity-modulated radiation therapy (IMRT) on the recurrence and survival in patients with lymph node positive or Stage III thoracic esophageal squamous cell carcinoma (TESCC), and evaluate the role of postoperative IMRT in the TESCC therapy. From January 2004 to June 2009, 535 patients with TESCC underwent radical resection with or without postoperative IMRT were eligible for analysis. Inclusion criteria: (1) having undergone radical resection (R0); (2) a diagnosis of squamous cell carcinoma confirmed by pathological studies; (3) Karnofsky performance status scale ≥70; (4) Preoperative neoadjuvant therapy was not proceeded; (5) postoperative pathologic stage was IIb or III. According to UICC02 stage classification, 122 patients were stage IIb and 413 patients were stage III. Patients were grouped to surgery alone (n = 345) and surgery plus postoperative IMRT (n = 190). The median total dose in postoperative IMRT was 60 Gy. The Kaplan-Meier method was used to calculate the survival rates, and the log-rank test was used for univariate analysis. The chi-square test was used to analyze the sites of failure of esophageal cancer with different treatments. The 1-, 3-, and 5-year overall survival (OS) and disease-free survival (DFS) for all the patients were 79.5%, 42.7%, 32.8%, and 67.2%, 38.0%, 32.5%, and the median OS and DFS were 28.6 months and 21.5 months, respectively. For patients with stage IIb and stage III, the 5-year OS rates were 45.3% and 29.2%, respectively (p = 0.001). The 5-year OS in the patients with lymph node positivity was 28.5% in the group receiving surgery alone and 38.9% in the group undergoing surgery plus postoperative IMRT (p = 0.000). The 5-year OS rates in patients with stage III was 24.3% in the surgery group and 38.0% in the surgery plus postoperative IMRT group, respectively (p = 0.001). Use of postoperative IMRT resulted in significant decrease in intrathoracic recurrence from 33.6% to 13.3% (p = 0.000) as well as supraclavicular recurrence from 13.4% to 6.1% (p = 0.012), Similarly, use of postoperative IMRT obviously delayed the median local recurrence from 10.7 months to 20.7 months and the median system metastases from 8.8 months to 14.5 months. While systemic metastases increased from 21.6% to 30.4% (p = 0.032) by postoperative IMRT treatment. Postoperative IMRT reduced local recurrence and improved survival for patients with lymph node positive or stage III TESCC, which would provide rationale in establishing patient selection criteria for the postoperative IMRT for TESCC after surgery.

Esophageal Squamous Cell Carcinoma Patients with Positive Lymph Nodes Benefit from Extended Radical Lymphadenectomy

Association of the Number of Dissected Lymph Node (LN) with the Survivals of Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) Patients Received Preoperative Chemoradiotherapy (CRT) Followed by Surgery.

Investigation To Metastasis Of Regional Lymph Node Station And Prediction To Long-Term Survival Following Esophagectomy In Thoracic Esophageal Cancer With Stage T1 To T3.

Extended Right Thoracic Approach Compared with Limited Left Thoracic Approach for Patients with Middle and Lower Esophageal Squamous Cell Carcinoma Three-year Survival of a Prospective, Randomized, Open-label Trial

373. STRATEGIES ON OPTIMAL LYMPHADENECTOMY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE ANALYSIS OF 1517 CASES IN A SINGLE CANCER CENTER

Prognostic Significance of Preoperative Lymph Node Assessment for Patients with Stage Pn0 Esophageal Squamous Cell Carcinoma after Esophagectomy.

Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: the Randomized Phase III RELARC Trial

Prognostic value of the extent of lymphadenectomy for esophageal cancer-specific survival among T1 patients

Prognostic Impact of Lymphadenectomy on Outcomes of Sublobar Resection for Stage IA Non–small Cell Lung Cancer ≤2 Cm

Postoperative Intensity Modulated Radiation Therapy Improved Survival of Lymph Node-Positive or Stage III Squamous Cell Carcinoma Esophagus

Influence of Metastatic Status and Number of Removed Lymph Nodes on Survival of Patients with Squamous Esophageal Carcinoma.

Extensive Mediastinal Lymphadenectomy During Minimally Invasive Esophagectomy: Optimal Results from a Single Center

Number of Retrieved Lymph Nodes during Esophagectomy Affects the Outcome of Stage III Esophageal Cancer in Patients Having Had Pre-Operative Chemo-Radiation Therapy

Number of Negative Lymph Nodes is Associated with Survival in Thoracic Esophageal Squamous Cell Carcinoma Patients Undergoing Three-Field Lymphadenectomy

Long-term Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Esophagectomy Following Neoadjuvant Chemotherapy: a Cohort Study

Impact of Lymph Node Dissection on Survival after Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Cervical lymph node metastasis classified as regional nodal staging in thoracic esophageal squamous cell carcinoma after radical esophagectomy and three-field lymph node dissection

The Number of Lymph Node Metastases Influences Survival and International Union Against Cancer Tumor-Node-metastasis Classification for Esophageal Squamous Cell Carcinoma: Does Lymph Node Yield Matter?

Extensive lymphadenectomy may improve survival in node negative oesophageal cancer

Surgical Quality Determines the Long-Term Survival Superiority of Right over Left Thoracic Esophagectomy for Localized Esophageal Squamous Cell Carcinoma Patients: a Real-World Multicenter Study.

Impact of Lymph Node Dissection on Survival after Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: from the Results of NEOCRTEC5010, a Randomized Multicenter Study.